Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ridgetech's enterprise value is €-7.2 Mil.
Ridgetech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was €0.8 Mil. Therefore, Ridgetech's EV-to-EBITDA for today is -9.55.
The historical rank and industry rank for Ridgetech's EV-to-EBITDA or its related term are showing as below:
FRA:7QL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.29 Med: -3.84 Max: 236.14
Current: -9.97
During the past 13 years, the highest EV-to-EBITDA of Ridgetech was 236.14. The lowest was -86.29. And the median was -3.84.
FRA:7QL's EV-to-EBITDA is ranked better than 99.61% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs FRA:7QL: -9.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ridgetech (FRA:7QL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ridgetech's share price for today is €20304.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ridgetech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was €312.297.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ridgetech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7QL vs DHTI, PMHS, BLMH: EV-to-EBITDA Comparison
For the Pharmaceutical Retailers subindustry, Ridgetech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ridgetech EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ridgetech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ridgetech's EV-to-EBITDA falls into.
Ridgetech's current Enterprise Value is €-7.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ridgetech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was €0.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ridgetech (FRA:7QL) has a EV-to-EBITDA of -9.55 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ridgetech. According to the industry distribution chart, Ridgetech ranks #2 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 0.40000000000001%.
Is Ridgetech's EV-to-EBITDA too high?
Ridgetech's current EV-to-EBITDA is -9.55. Based on the distribution chart, Ridgetech ranks #2 out of 507 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Ridgetech has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Ridgetech's EV-to-EBITDA compare to DHTI and PMHS?
According to the Healthcare Providers & Services industry distribution chart, Ridgetech ranks #2 out of 507 companies for EV-to-EBITDA. This places Ridgetech in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ridgetech. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ridgetech's current EV-to-EBITDA is -9.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ridgetech stock overvalued right now?
Ridgetech (FRA:7QL) has a current EV-to-EBITDA of -9.55. The stock's GF Value™ is €2,118,249.18, compared to a current price of €20,304.00 — trading 99% below its estimated fair value. The current EV-to-EBITDA is -9.55. Ridgetech's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ridgetech (FRA:7QL), the current EV-to-EBITDA is -9.55 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ridgetech (FRA:7QL) Overvalued in 2026?
Based on GuruFocus' analysis, Ridgetech stock appears to be undervalued.
The current stock price of €20,304.00 is trading 99% below its estimated GF Value™ of €2,118,249.18.
Key valuation signals for FRA:7QL:
EV-to-EBITDA: -9.55
GF Value™: €2,118,249.18 vs. price of €20,304.00 (99% below fair value)
No single metric tells the full story. See the FRA:7QL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ridgetech Inc formerly China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.
40GF Score
Get the complete analysis for FRA:7QL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7QL has been successfully added to your 
